Refine
Year of publication
Document Type
- Preprint (666)
- Article (376)
- Working Paper (1)
Language
- English (1043)
Has Fulltext
- yes (1043)
Is part of the Bibliography
- no (1043)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- ALICE experiment (4)
- Collective Flow (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- Heavy Ions (3)
- Jets and Jet Substructure (3)
- pp collisions (3)
- ACLF (2)
- Beauty production (2)
- Charm physics (2)
- Epilepsy (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- Heavy Quark Production (2)
- Lepton-Nucleon Scattering (experiments) (2)
- NASH (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- QCD (2)
- Seizure (2)
- Single electrons (2)
- epilepsy (2)
- 1,4-naphthoquinone (1)
- 900 GeV (1)
- ALICE detector (1)
- Angiomyolipoma (1)
- Anti-nuclei (1)
- Anti-seizure medication (1)
- Anticonvulsant (1)
- Boosted Jets (1)
- CD4 binding site (1)
- CVID (1)
- Centrality Class (1)
- Centrality Selection (1)
- Collective Flow, (1)
- Comparison with QCD (1)
- Costs (1)
- Electron-pion identification (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- European Society for Immunodeficiencies (ESID) (1)
- Everolimus (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Genetics (1)
- German PID-NET registry (1)
- HBT (1)
- HIV-1 (1)
- HIV-1 escape restriction (1)
- HVPG (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hard Scattering (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- IgG substitution therapy (1)
- Inclusive spectra (1)
- Intensity interferometry (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Jet Physics (1)
- Jet Substructure (1)
- Lafora disease (1)
- MTOR inhibitor (1)
- Material budget (1)
- Mid-rapidity (1)
- Minimum Bias (1)
- Monte Carlo (1)
- Multi-Parton Interactions (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- NAFLD (1)
- Neural network (1)
- Nuclear modification factor (1)
- PID prevalence (1)
- PYTHIA (1)
- Particle and Resonance Production (1)
- Pb–Pb (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Proton–proton (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- Rapidity Range (1)
- Relativistic heavy ion physics (1)
- Relativistic heavy-ion collisions (1)
- Resolution Parameter (1)
- Rhabdomyoma (1)
- Roux-en-Y gastric bypass (1)
- Single muons (1)
- Sociodemographic characteristics (1)
- Subependymal giant cell astrocytoma (1)
- Systematic Uncertainty (1)
- TR (1)
- TSC (1)
- Time Projection Chamber (1)
- Tracking (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Vector Boson Production (1)
- Xenon-based gas mixture (1)
- acute decompensation (1)
- anticonvulsants (1)
- bacterial translocation (1)
- broadly neutralizing antibodies (1)
- cirrhosis (1)
- covalent reversible inhibition (1)
- cryogenic electron microscopy (1)
- dE/dx (1)
- deep mutational scanning (1)
- detector (1)
- epileptic encephalopathies (1)
- escape mutations (1)
- experimental results (1)
- fibrosis (1)
- genetics (1)
- heavy ion experiments (1)
- hepatic stellate cells (1)
- hepatocellular cancer (1)
- humanized mice (1)
- immunotherapy (1)
- in vitro models (1)
- inflammation (1)
- intestinal manipulation (1)
- juvenile myoclonic epilepsy (1)
- levetiracetam (1)
- mTOR inhibitor (1)
- mini gastric bypass (1)
- mutational antigenic profiling (1)
- nucleophilic addition (1)
- one anastomosis gastric bypass (1)
- pharmacoresistance (1)
- portal pressure (1)
- primary immunodeficiency (PID) (1)
- prodrug (1)
- progressive myoclonus epilepsy (1)
- protease (1)
- quark gluon plasma (1)
- registry for primary immunodeficiency (1)
- rhodesain (1)
- seizure (1)
- spectra (1)
- steatosis (1)
- surgery (1)
- weight loss (1)
- √sN N = 2.76 TeV (1)
- fibrogenesis (1)
Institute
- Physik (1025)
- Frankfurt Institute for Advanced Studies (FIAS) (955)
- Informatik (921)
- Medizin (16)
- Informatik und Mathematik (3)
- Hochschulrechenzentrum (2)
- Biowissenschaften (1)
- Center for Financial Studies (CFS) (1)
- House of Finance (HoF) (1)
- Pharmazie (1)
Objective: To evaluate the efficacy and tolerability of brivaracetam (BRV) in a severely drug refractory cohort of patients with epileptic encephalopathies (EE).
Method: A multicenter, retrospective cohort study recruiting all patients treated with EE who began treatment with BRV in an enrolling epilepsy center between 2016 and 2017.
Results: Forty-four patients (27 male [61%], mean age 29 years, range 6 to 62) were treated with BRV. The retention rate was 65% at 3 months, 52% at 6 months and 41% at 12 months. A mean retention time of 5 months resulted in a cumulative exposure to BRV of 310 months. Three patients were seizure free during the baseline. At 3 months, 20 (45%, 20/44 as per intention-to-treat analysis considering all patients that started BRV including three who were seizure free during baseline) were either seizure free (n = 4; 9%, three of them already seizure-free at baseline) or reported at least 25% (n = 4; 9%) or 50% (n = 12; 27%) reduction in seizures. An increase in seizure frequency was reported in two (5%) patients, while there was no change in the seizure frequency of the other patients. A 50% long-term responder rate was apparent in 19 patients (43%), with two (5%) free from seizures for more than six months and in nine patients (20%, with one [2 %] free from seizures) for more than 12 months. Treatment-emergent adverse events were predominantly of psychobehavioural nature and were observed in 16%.
Significance: In this retrospective analysis the rate of patients with a 50% seizure reduction under BRV proofed to be similar to those seen in regulatory trials for focal epilepsies. BRV appears to be safe and relatively well tolerated in EE and might be considered in patients with psychobehavioral adverse events while on levetiracetam.